--- title: "Obicetrapib | PepTracker Pro" url: https://peptrackerpro.com/peptides/obicetrapib description: "An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Obicetrapib Medium Evidence An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026. Aliases TA-8995 +5 more Evidence Medium Evidence Last Updated 2026-08-10 Reading Time 6 min ## What It Is Obicetrapib (formerly TA-8995 and AMG 899, and marketed in Europe under the brand names Ubeslo for the monotherapy and Evlarco for the ezetimibe combination) is an investigational once-daily oral, highly selective inhibitor of cholesteryl ester transfer protein (CETP), developed by NewAmsterdam Pharma with Menarini Group as its European partner. CETP is a plasma protein that shuttles cholesteryl esters from HDL particles to LDL and other apolipoprotein B (apoB)-containing particles. Blocking it lowers LDL cholesterol, non-HDL cholesterol, apoB and, importantly, lipoprotein(a) [Lp(a)], while raising HDL cholesterol. CETP inhibition has a hard history: torcetrapib (Pfizer), dalcetrapib (Roche), evacetrapib (Eli Lilly) and anacetrapib (Merck) were all abandoned - torcetrapib because it raised blood pressure and cardiovascular events in the ILLUMINATE trial - and the field's original 'raise HDL' hypothesis largely collapsed. Obicetrapib represents the rebirth of the class, but with a reframed rationale: its value is LDL and Lp(a) lowering, not HDL raising. NewAmsterdam, founded by lipid experts John Kastelein and Michael Davidson, acquired obicetrapib from Amgen and developed it as an oral add-on for patients already on maximally tolerated statins (and often ezetimibe) who are not at their LDL goal. In the pivotal Phase 3 BROADWAY trial (2,530 adults with ASCVD or heterozygous familial hypercholesterolemia; 10 mg once daily vs placebo for one year), obicetrapib lowered LDL-C by 29.9% at day 84 (vs +2.7% with placebo, a placebo-adjusted reduction of roughly a third) and cut Lp(a) by 33.5% versus placebo, with a numerically lower - though underpowered - rate of cardiovascular events (4.2% vs 5.2%; HR 0.79, 95% CI 0.54-1.15). In the Phase 3 TANDEM trial (407 adults), a fixed-dose combination of obicetrapib plus ezetimibe reduced LDL-C by 48.6% versus placebo - about half - while obicetrapib monotherapy lowered it by 31.9%. The earlier BROOKLYN trial had already shown marked LDL-C lowering in heterozygous familial hypercholesterolemia. BROADWAY and TANDEM were presented at the European Atherosclerosis Society Congress 2025 and published simultaneously in the New England Journal of Medicine and The Lancet. Because obicetrapib lowers both LDL and Lp(a) by at least about 30% in a single oral pill, it is being positioned for people with elevated levels of both who may not qualify for - or prefer not to use - the injectable Lp(a) therapies. On July 24, 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe) for primary hypercholesterolemia and mixed dyslipidemia, with a final European Commission decision expected in the second half of 2026; MHRA and Swissmedic decisions are also anticipated in H2 2026. The pivotal Phase 3 PREVAIL cardiovascular outcomes trial (~9,541 adults with established ASCVD, enrollment completed in April 2024, testing whether obicetrapib reduces major adverse cardiovascular events) is ongoing, with results expected in 2026 - the study that will determine whether obicetrapib's dual LDL/Lp(a) lowering actually prevents events. Obicetrapib is a clinical-stage prescription medicine and, pending the European Commission decision, is not yet approved anywhere; it is not a supplement or research chemical. Also known as: TA-8995, AMG 899, DEZ-001, Ubeslo, Evlarco (with ezetimibe), oral CETP inhibitor ## Regulatory Status Investigational - positive CHMP opinion (EU), not yet approved Obicetrapib is not yet approved anywhere. Marketing authorization applications were submitted to the EMA by Menarini in August 2025, and on July 24, 2026 the EMA's CHMP issued a positive opinion recommending approval of Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) for primary hypercholesterolemia and mixed dyslipidemia; a final European Commission decision is expected in the second half of 2026, with MHRA and Swissmedic decisions also anticipated in H2 2026. Robust LDL-C and Lp(a) lowering are established across the Phase 3 BROADWAY (NEJM 2025), TANDEM (Lancet 2025) and BROOKLYN trials; the Phase 3 PREVAIL cardiovascular outcomes trial (~9,541 patients) is ongoing with results expected in 2026. Developed by NewAmsterdam Pharma (which acquired it from Amgen); commercialized in Europe by Menarini Group. Effective: 2026 View FDA Source (https://www.globenewswire.com/news-release/2026/07/24/3332807/0/en/NewAmsterdam-Pharma-and-Menarini-Group-Receive-Positive-CHMP-Opinion-Recommending-Marketing-Authorization-for-Ubeslo-Obicetrapib-Monotherapy-and-Evlarco-Obicetrapib-Plus-Ezetimibe-.html) ## Why Researchers Study It Obicetrapib is the drug that revived CETP inhibition - a target left for dead after torcetrapib raised blood pressure and cardiovascular events and after dalcetrapib, evacetrapib and anacetrapib were abandoned. What makes it interesting is not the old 'raise HDL' idea (now discredited) but that a single once-daily oral pill lowers both LDL cholesterol and lipoprotein(a) by at least roughly 30% - two independent, causal drivers of atherosclerotic cardiovascular disease. That dual, oral action fills a specific gap: many people with moderately elevated Lp(a) are not eligible for the injectable Lp(a)-lowering therapies (which enroll only very high Lp(a) levels) and would prefer a pill to periodic injections. Researchers study obicetrapib to see whether an accessible oral agent that nudges Lp(a) down while substantially cutting LDL can reduce real cardiovascular events - the question the ongoing PREVAIL outcomes trial is designed to answer - and, separately, because signals from BROADWAY on Alzheimer's-related biomarkers have prompted interest in CETP inhibition beyond the heart. ## Proposed Mechanisms - Highly selective oral inhibitor of cholesteryl ester transfer protein (CETP), taken once daily (10 mg) - Blocks CETP-mediated transfer of cholesteryl esters from HDL to LDL and other apoB-containing particles - Lowers LDL cholesterol, non-HDL cholesterol and apolipoprotein B, and raises HDL cholesterol - Reduces lipoprotein(a) [Lp(a)] by roughly a third - an effect independent of its LDL lowering - Used as an oral add-on to maximally tolerated statins (and often ezetimibe) to reach LDL goals and lower residual cardiovascular risk ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 3 (BROADWAY, NEJM 2025) | 2,530 adults with ASCVD (89%) or heterozygous familial hypercholesterolemia (17%) on maximally tolerated lipid-lowering therapy; obicetrapib 10 mg once daily vs placebo for 1 year | LDL-C -29.9% with obicetrapib vs +2.7% with placebo at day 84 (placebo-adjusted ~ -32.6%), maintained to 1 year; Lp(a) -33.5% vs placebo; cardiovascular events numerically lower but underpowered (4.2% vs 5.2%; HR 0.79, 95% CI 0.54-1.15); well tolerated. Presented at EAS 2025 | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2415820 | | Phase 3 (TANDEM, The Lancet 2025) | 407 adults with heterozygous FH or ASCVD (or high risk) on maximally tolerated therapy; fixed-dose obicetrapib 10 mg + ezetimibe 10 mg vs obicetrapib, ezetimibe, or placebo over 84 days | Fixed-dose combination lowered LDL-C by 48.6% vs placebo (27.9% vs ezetimibe, 16.8% vs obicetrapib alone); obicetrapib monotherapy -31.9% vs placebo; low, comparable serious adverse event rates. Presented at EAS 2025 | Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00721-4/abstract | | Phase 3 (BROOKLYN) | Adults with heterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy; obicetrapib 10 mg once daily vs placebo | Significant, marked LDL-C lowering in a difficult-to-treat genetic population; supported the pivotal program and regulatory filings | Source: https://www.menarini.com/en-us/news/news-detail/menarini-announces-positive-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-efficacy-safety-and-tolerability-of-obicetrapib-in-patients-with-heterozygous-familial.html | | Phase 3 cardiovascular outcomes (PREVAIL) - ongoing | ~9,541 adults with established ASCVD on standard-of-care lipid therapy; obicetrapib 10 mg once daily vs placebo; primary endpoint major adverse cardiovascular events | Tests whether obicetrapib's dual LDL/Lp(a) lowering reduces cardiovascular death, myocardial infarction, stroke and coronary revascularization; enrollment completed April 2024, results expected in 2026 | Source: https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-doses-first-patient-prevail-cardiovascular | ## Commonly Discussed Benefits Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Disease Modification: https://peptrackerpro.com/benefits/disease-modification Researching Obicetrapib? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=obicetrapib) ## Safety & Cautions - Investigational - not yet approved anywhere; a positive EMA CHMP opinion was issued in July 2026 (as Ubeslo and Evlarco) but the final European Commission decision is pending - Robust LDL-C and Lp(a) lowering are established, but whether obicetrapib reduces actual cardiovascular events is still being tested in the ongoing Phase 3 PREVAIL outcomes trial and is not yet proven - Belongs to the CETP-inhibitor class whose first generation (torcetrapib, dalcetrapib, evacetrapib, anacetrapib) failed; obicetrapib has been well tolerated in Phase 3 but its long-term outcome and safety profile await PREVAIL - A prescription clinical-stage medicine taken as a daily oral pill under medical supervision - not a supplement, nootropic, or research chemical - Any 'obicetrapib', 'TA-8995' or 'AMG 899' offered by a research-chemical vendor is unverified and not a legitimate source of this medicine - Lowers Lp(a) by only about a third - far less than the injectable Lp(a)-specific therapies - so it is positioned for moderately elevated Lp(a) plus high LDL, not as a maximal Lp(a) treatment ## Comparisons See how Obicetrapib compares to related peptides: Obicetrapib vs Enlicitide: https://peptrackerpro.com/compare/obicetrapib-vs-enlicitide Obicetrapib vs Inclisiran: https://peptrackerpro.com/compare/obicetrapib-vs-inclisiran Obicetrapib vs Lepodisiran: https://peptrackerpro.com/compare/obicetrapib-vs-lepodisiran Obicetrapib vs Muvalaplin: https://peptrackerpro.com/compare/obicetrapib-vs-muvalaplin Obicetrapib vs Olezarsen: https://peptrackerpro.com/compare/obicetrapib-vs-olezarsen Obicetrapib vs Olpasiran: https://peptrackerpro.com/compare/obicetrapib-vs-olpasiran Obicetrapib vs Pelacarsen: https://peptrackerpro.com/compare/obicetrapib-vs-pelacarsen Obicetrapib vs Plozasiran: https://peptrackerpro.com/compare/obicetrapib-vs-plozasiran Obicetrapib vs Solbinsiran: https://peptrackerpro.com/compare/obicetrapib-vs-solbinsiran Obicetrapib vs Zerlasiran: https://peptrackerpro.com/compare/obicetrapib-vs-zerlasiran Obicetrapib vs Ziltivekimab: https://peptrackerpro.com/compare/obicetrapib-vs-ziltivekimab Obicetrapib vs Zodasiran: https://peptrackerpro.com/compare/obicetrapib-vs-zodasiran ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Nicholls SJ, et al. - Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk (BROADWAY, Phase 3), New England Journal of Medicine (2025) PubMed (https://www.nejm.org/doi/full/10.1056/NEJMoa2415820) 2. [2] Sarraju A, et al. - Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM, Phase 3), The Lancet (2025) PubMed (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00721-4/abstract) 3. [3] NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib + ezetimibe) - July 24, 2026 PubMed (https://www.globenewswire.com/news-release/2026/07/24/3332807/0/en/NewAmsterdam-Pharma-and-Menarini-Group-Receive-Positive-CHMP-Opinion-Recommending-Marketing-Authorization-for-Ubeslo-Obicetrapib-Monotherapy-and-Evlarco-Obicetrapib-Plus-Ezetimibe-.html) 4. [4] NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with ASCVD PubMed (https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-doses-first-patient-prevail-cardiovascular) 5. [5] Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM - TCTMD (2025) PubMed (https://www.tctmd.com/news/back-brink-obicetrapib-performs-well-broadway-tandem) ### Keep researching in the app - Log Obicetrapib to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=obicetrapib Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Enlicitide High Evidence An oral PCSK9 inhibitor peptide that reduced LDL cholesterol by 57% in Phase 3 trials — matching injectable monoclonal antibodies in efficacy while offering once-daily pill convenience. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/enlicitide \+ Compare: https://peptrackerpro.com/compare?select=enlicitide Track in App: https://app.peptrackerpro.com/?add=enlicitide ### Inclisiran High Evidence An approved, twice-yearly subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Novartis (originally discovered by Alnylam) that lowers LDL cholesterol by silencing PCSK9 (proprotein convertase subtilisin/kexin type 9), the liver protein that destroys LDL receptors. By switching off PCSK9 production inside hepatocytes, inclisiran leaves more LDL receptors on the liver surface to pull LDL cholesterol out of the blood - achieving roughly a 50% LDL reduction with an injection given only twice a year after a loading dose. Marketed as Leqvio, it was the first siRNA medicine approved for a chronic cardiovascular condition: the EU cleared it in December 2020 and the FDA in December 2021, and in July 2025 the FDA expanded the U.S. label to first-line monotherapy, dropping the requirement that it be added on top of a statin. Its Phase 3 ORION-9, ORION-10 and ORION-11 trials established the LDL benefit; a large cardiovascular outcomes program (VICTORION-2-PREVENT and others) is still running to test whether that LDL lowering prevents heart attacks and strokes. Inclisiran is the approved, real-world proof-of-concept for the GalNAc-siRNA cardiometabolic platform that newer investigational agents like zodasiran, solbinsiran, olpasiran and plozasiran build on. View Details: https://peptrackerpro.com/peptides/inclisiran \+ Compare: https://peptrackerpro.com/compare?select=inclisiran Track in App: https://app.peptrackerpro.com/?add=inclisiran ### Lepodisiran Medium Evidence An investigational, long-duration injectable small interfering RNA (siRNA) from Eli Lilly that lowers lipoprotein(a) [Lp(a)] by nearly 94% by silencing the LPA gene in the liver. A single dose keeps Lp(a) suppressed for a year or more, and its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes trial to include people who have not yet had a cardiovascular event. View Details: https://peptrackerpro.com/peptides/lepodisiran \+ Compare: https://peptrackerpro.com/compare?select=lepodisiran Track in App: https://app.peptrackerpro.com/?add=lepodisiran ### Muvalaplin Medium Evidence The first oral, small-molecule inhibitor of lipoprotein(a) [Lp(a)] formation, from Eli Lilly. Instead of silencing a gene, muvalaplin is a once-daily pill that physically blocks apolipoprotein(a) from binding apolipoprotein B — the first step in building an Lp(a) particle. In its Phase 2 KRAKEN trial (published in JAMA, 2024) it cut Lp(a) by up to ~86% (placebo-adjusted) and, as of 2026, is the only Lp(a)-lowering drug that is both oral and already enrolling a large Phase 3 cardiovascular outcomes trial (MOVE-Lp(a)). View Details: https://peptrackerpro.com/peptides/muvalaplin \+ Compare: https://peptrackerpro.com/compare?select=muvalaplin Track in App: https://app.peptrackerpro.com/?add=muvalaplin ### Olezarsen High Evidence An FDA-approved subcutaneous antisense oligonucleotide (ASO) from Ionis Pharmaceuticals, branded Tryngolza, that lowers triglycerides by silencing the messenger RNA for apolipoprotein C-III (apoC-III). Self-injected once a month, it was the first-ever therapy approved for familial chylomicronemia syndrome (FCS) on December 19, 2024, and on June 24, 2026 it became the first and only treatment approved to reduce both triglycerides and the risk of acute pancreatitis in the far larger severe hypertriglyceridemia (sHTG) population. View Details: https://peptrackerpro.com/peptides/olezarsen \+ Compare: https://peptrackerpro.com/compare?select=olezarsen Track in App: https://app.peptrackerpro.com/?add=olezarsen ### Olpasiran Medium Evidence An investigational, once-every-12-weeks injectable small interfering RNA (siRNA) from Amgen that lowers lipoprotein(a) [Lp(a)] by up to ~97% by silencing the LPA gene in the liver. Its Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial (~7,000 patients) is one of the pivotal readouts — due December 2026 — that will help decide whether lowering Lp(a) prevents heart attacks and strokes. View Details: https://peptrackerpro.com/peptides/olpasiran \+ Compare: https://peptrackerpro.com/compare?select=olpasiran Track in App: https://app.peptrackerpro.com/?add=olpasiran ### Pelacarsen Medium Evidence A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026. View Details: https://peptrackerpro.com/peptides/pelacarsen \+ Compare: https://peptrackerpro.com/compare?select=pelacarsen Track in App: https://app.peptrackerpro.com/?add=pelacarsen ### Plozasiran High Evidence An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population. View Details: https://peptrackerpro.com/peptides/plozasiran \+ Compare: https://peptrackerpro.com/compare?select=plozasiran Track in App: https://app.peptrackerpro.com/?add=plozasiran ### Solbinsiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program. View Details: https://peptrackerpro.com/peptides/solbinsiran \+ Compare: https://peptrackerpro.com/compare?select=solbinsiran Track in App: https://app.peptrackerpro.com/?add=solbinsiran ### Zerlasiran Medium Evidence An investigational, long-acting injectable small interfering RNA (siRNA) from Silence Therapeutics that lowers lipoprotein(a) [Lp(a)] by more than 80% by silencing the LPA gene in the liver. Dosed only every 16–24 weeks, it produced durable ~90% reductions in its Phase 2 ALPACAR-360 trial (published in JAMA, 2024); as of 2026 the company is seeking a partner before starting its Phase 3 cardiovascular outcomes study. View Details: https://peptrackerpro.com/peptides/zerlasiran \+ Compare: https://peptrackerpro.com/compare?select=zerlasiran Track in App: https://app.peptrackerpro.com/?add=zerlasiran ### Ziltivekimab Medium Evidence An investigational, fully human monoclonal antibody that neutralizes the pro-inflammatory cytokine interleukin-6 (IL-6) to test whether lowering vascular inflammation - independently of cholesterol - can prevent heart attacks, strokes and cardiovascular death. Given as a low-volume, once-monthly 15 mg subcutaneous injection (half-life ~57 days), ziltivekimab was originally developed by Corvidia Therapeutics and acquired by Novo Nordisk in 2020 for up to $2.1 billion. It is the flagship clinical test of the 'residual inflammatory risk' hypothesis that grew out of the CANTOS trial of the IL-1 beta antibody canakinumab: the idea that many high-risk patients keep having cardiovascular events because of ongoing inflammation (marked by high-sensitivity C-reactive protein, hsCRP) even when LDL cholesterol is well controlled. In the Phase 2 RESCUE trial ziltivekimab cut hsCRP by up to ~92%, and it advanced into three large Phase 3 cardiovascular outcomes trials - ZEUS, HERMES and ARTEMIS. On July 31, 2026, Novo Nordisk announced that the pivotal ZEUS trial (>6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation) MISSED its primary endpoint: despite clear target engagement (large falls in free IL-6 and hsCRP), ziltivekimab did not reduce major adverse cardiovascular events versus placebo (hazard ratio 0.99, 95% CI 0.88-1.11). The heart-failure trial HERMES and the post-heart-attack trial ARTEMIS continue, with readouts expected in the first half of 2027. Ziltivekimab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. Inflammation: https://peptrackerpro.com/benefits/inflammation Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management View Details: https://peptrackerpro.com/peptides/ziltivekimab \+ Compare: https://peptrackerpro.com/compare?select=ziltivekimab Track in App: https://app.peptrackerpro.com/?add=ziltivekimab ### Zodasiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Arrowhead Pharmaceuticals that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made regulator of fat metabolism. By switching off ANGPTL3 production, zodasiran deeply reduces triglycerides, remnant cholesterol and LDL cholesterol through a pathway that does not depend on the LDL receptor - making it especially relevant for people, such as those with homozygous familial hypercholesterolemia (HoFH), whose LDL receptors barely work. In the Phase 2b ARCHES-2 trial (NEJM 2024) it produced durable, dose-dependent reductions in triglycerides, remnant cholesterol and ANGPTL3, and in the Phase 2 GATEWAY study it lowered LDL cholesterol by about 40% in HoFH. It is now in the Phase 3 YOSEMITE trial in HoFH, which completed enrollment in July 2026. View Details: https://peptrackerpro.com/peptides/zodasiran \+ Compare: https://peptrackerpro.com/compare?select=zodasiran Track in App: https://app.peptrackerpro.com/?add=zodasiran ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Obicetrapib", "description": "An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026.", "url": "https://peptrackerpro.com/peptides/obicetrapib", "lastReviewed": "2026-08-10", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Obicetrapib", "item": "https://peptrackerpro.com/peptides/obicetrapib" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People with high LDL cholesterol who have not reached goal on statins (and ezetimibe) and want an oral add-on option?", "acceptedAnswer": { "@type": "Answer", "text": "Obicetrapib is a research peptide studied in preclinical models. An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026." } }, { "@type": "Question", "name": "Those with moderately elevated lipoprotein(a) who do not qualify for the injectable Lp(a) therapies but want a pill that lowers it somewhat while cutting LDL?", "acceptedAnswer": { "@type": "Answer", "text": "Obicetrapib is a research peptide studied in preclinical models. An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026." } }, { "@type": "Question", "name": "Clinicians tracking the rebirth of CETP inhibition and comparing obicetrapib with the failed first-generation drugs?", "acceptedAnswer": { "@type": "Answer", "text": "Obicetrapib is a research peptide studied in preclinical models. An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026." } }, { "@type": "Question", "name": "Those comparing obicetrapib (an oral CETP inhibitor lowering both LDL and Lp(a)) with the Lp(a)-specific agents muvalaplin, pelacarsen, olpasiran, lepodisiran and zerlasiran and the oral PCSK9 inhibitor enlicitide?", "acceptedAnswer": { "@type": "Answer", "text": "Obicetrapib is a research peptide studied in preclinical models. An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026." } } ] } ] ```